The Consumer Advisor

Based on year-to-date (YTD) performance as of October 2025, here are the top 10 precious metal ETFs. These focus on commodity-tracking funds (physical or futures-based), ranked by YTD returns. Miners and leveraged ETFs are excluded, as they represent different strategies. Performance figures are approximate and reflect the underlying metal's price movements minus expenses. Key metrics include ticker, name, primary metal(s), YTD return, AUM, expense ratio, valuation and recommendation to buy, hold or sell. As we enter Q4 2025, gold prices have rallied way above $4,000 per ounce, with analysts forecasting potential climbs above $4,100 by year-end amid ongoing geopolitical tensions, central bank buying, and economic uncertainty. Silver, often called "gold's little brother," has rallied above $50 per ounce, driven by industrial demand in solar and electronics, with projections for prices to reach $$55 per ounce by the end of October and potentially higher into November. 1...

Here are the top 10 pharmaceutical companies as of 2025, updated based on second quarter 2025 revenue data. AstraZeneca, Novartis and Vertex each posted 12% sales increases, offering more evidence of their upward trajectories in recent years. Credit:  fiercepharma.com Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 ,  2 ,  3 ). Updates: Drug Stock Rally Helps Push Dow and S&P 500 to Records — WSJ ( Oct 2, 2025 ) Eli Lilly's (LLY) shares jumped 8.6% amid reports of a drug-pricing deal between the White House and the pharmaceutical industr...